Dysequilibrium syndrome

Dysequilibrium syndrome (DES), also known as non-progressive cerebellar ataxia with intellectual disability, is a rare autosomal recessive neurological disorder characterized by severe impairment of balance and coordination (cerebellar ataxia), intellectual disability, and delayed motor development. Affected individuals typically have significant difficulty walking, and many never achieve independent ambulation or walk only with substantial support. The condition is caused by cerebellar hypoplasia — underdevelopment of the cerebellum, the brain region responsible for coordinating movement and maintaining balance. Several genetic subtypes have been identified, including DES type 1 (caused by mutations in the VLDLR gene), DES type 2 (caused by mutations in the CA8 gene), DES type 3 (WDR81 gene), and DES type 4 (ATP8A2 gene). The VLDLR-associated form is the most well-characterized and has been described particularly in consanguineous families. In addition to cerebellar ataxia and intellectual disability, patients may exhibit strabismus (crossed eyes), short stature, seizures, and dysarthria (difficulty with speech). Brain imaging typically reveals cerebellar hypoplasia, which may be particularly prominent in the inferior vermis. There is currently no cure or disease-specific treatment for dysequilibrium syndrome. Management is supportive and multidisciplinary, including physical therapy to maximize mobility, occupational therapy, speech therapy, and educational support for intellectual disability. Antiepileptic medications may be used if seizures are present. Orthopedic interventions and assistive devices can help with ambulation. Genetic counseling is recommended for affected families, particularly those with consanguinity.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Dysequilibrium syndrome